| 79.49 Data as of May 17 |  +1.60 / +2.05%Today’s Change | 38.44 Today|||52-Week Range 87.47 | +89.71% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $17.6B |
Vertex Pharmaceuticals, Inc. 130 Waverly Street Cambridge Massachusetts 02139-4242 |
| Mutual fund holders | 57.09% |
| Other institutional | 34.24% |
| Individual stakeholders | 1.20% |
| Jeff M. Leiden, PhD, MD | Chairman, President & Chief Executive Officer |
| Ian F. Smith, CPA | Chief Financial Officer & Executive Vice President |
| Robert Kauffman, MD, PhD | Chief Medical Officer & Senior Vice President |
| Peter Mueller, PhD | Chief Scientific Officer |
| Stuart A. Arbuckle | Chief Commercial Officer & Executive VP |
.
